Janux Therapeutics, Inc. (JANX): R&D Expense
$125.90M
Year ended 2025-12-31
$123.98M
Trailing 12 months to 2026-06-30
+33.1%
3-year compound annual growth
+110.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $125.90M | +84.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $68.39M | +24.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $54.92M | +2.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $53.44M | +103.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $26.24M | +762.8% | 2023-03-10, From 2021-01-01 |
| 2020-12-31 | $3.04M | n/a | 2022-03-18, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $125.90M | +84.1% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $168.06M | +20.8% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $41.33M | -22.1% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $134.85M | -39.4% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $138.09M | +868.4% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $684.0K | +4.1% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $73.97M | +25.3% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $24.97M | +50.9% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $681.81M | +23.9% |
Compare JANX, ZBIO, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗